Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin

Within cohort 1 patients received the vaccine intradermally; in cohort 2 the route of Administration was intravenous Infusion, half of the patients had additional loading with RNA coding for EL-Selektin; in cohort 3 the vaccines was again infused intravenously, the cells were matured not with MCM.mimic as in cohort 1 and 2 but either with TriMix or MCM-mimic plus CD40L-RNA.

Trial Locations (1)

D-91052

Dermatologische Klinik mit Poliklinik - Universitaetsklinikum Erlangen, Erlangen

All Listed Sponsors
lead

University Hospital Erlangen

OTHER

NCT00074230 - Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma | Biotech Hunter | Biotech Hunter